Use of antipsychotics and risk of venous thromboembolism in postmenopausal women

Summary

Despite continued uncertainty of venous thromboembolism (VTE) caused from antipsychotic agents, this safety issue has not been examined in postmenopausal women, a population with high usages of antipsychotics and at high risk for VTE. We assessed whether antipsychotic use was associated with an increased VTE risk in women after menopause. We conducted a nested case-control study of all Taiwanese women aged ≥ 50 years (n = 316,132) using a nationwide healthcare claims database between 2000 and 2011. All newly diagnosed VTE patients treated with an anticoagulant or thrombectomy surgery were identified as cases (n = 2,520) and individually matched to select controls (n = 24,223) by cohort entry date, age, cancer diagnosis and major surgery procedure. The odds ratios (ORs) and 95 % confidence interval (CI) of VTE associated with antipsychotics were estimated by multivariate conditional logistic regressions. Current use of antipsychotics was associated with a 1.90-fold (95 % CI = 1.64–2.19) increased VTE risk compared with nonuse in postmenopausal women. The VTE risk existed in a dose-dependent fashion (test for trend, p<0.001), with a more than quadrupled risk for high-dose antipsychotics (adjusted OR = 4.60; 95 % CI = 2.88–7.33). Current parenteral administration of antipsychotics also led to a 3.46-fold increased risk (95 % CI = 2.39–5.00). Conversely, there was no increased VTE risk when antipsychotics were discontinued for > 30 days. In conclusion, current use of antipsychotics is significantly associated with a dose-dependent increased risk of VTE in postmenopausal women, especially for those currently taking high-dose or receiving parenteral antipsychotics.

Keywords

Venous thromboembolism (VTE) - nested case-control - antipsychotics - postmenopause - epidemiology

• References

• 1 Tagalakis V, Patenaude V, Kahn SR. et al. Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort. Am J Med 2013; 126 832 e13-21.
• 2 Lefebvre P, Laliberte F, Nutescu EA. et al. All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries. J Manag Care Pharm 2012; 18: 363-374.
• 3 Kearon C. Natural history of venous thromboembolism. Circulation 2003; 107: I22-30.
• 4 Allenet B, Schmidlin S, Genty C. et al. Antipsychotic drugs and risk of pulmonary embolism. Pharmacoepidemiol Drug Saf 2012; 21: 42-48.
• 5 Barbui C, Conti V, Cipriani A. Antipsychotic drug exposure and risk of venous thromboembolism: a systematic review and meta-analysis of observational studies. Drug Saf 2014; 37: 79-90.
• 6 Lacut K, Le Gal G, Couturaud F. et al. Association between antipsychotic drugs, antidepressant drugs and venous thromboembolism: results from the EDITH case-control study. Fundam Clin Pharmacol 2007; 21: 643-650.
• 7 Parker C, Coupland C, Hippisley-Cox J. Antipsychotic drugs and risk of venous thromboembolism: nested case-control study. Br Med J 2010; 341: c4245.
• 8 Parkin L, Skegg DC, Herbison GP. et al. Psychotropic drugs and fatal pulmonary embolism. Pharmacoepidemiol Drug Saf 2003; 12: 647-652.
• 9 Zhang R, Dong L, Shao F. et al. Antipsychotics and venous thromboembolism risk: a meta-analysis. Pharmacopsychiatry 2011; 44: 183-188.
• 10 Jonsson AK, Spigset O, Hagg S. Venous thromboembolism in recipients of antipsychotics: incidence, mechanisms and management. CNS Drugs 2012; 26: 649-662.
• 11 Kleijer BC, Heerdink ER, Egberts TC. et al. Antipsychotic drug use and the risk of venous thromboembolism in elderly patients. J Clin Psychopharmacol 2010; 30: 526-530.
• 12 Ray JG, Mamdani MM, Yeo EL. Antipsychotic and antidepressant drug use in the elderly and the risk of venous thromboembolism. Thromb Haemost 2002; 88: 205-209.
• 13 Schmedt N, Garbe E. Antipsychotic drug use and the risk of venous thromboembolism in elderly patients with dementia. J Clin Psychopharmacol 2013; 33: 753-758.
• 14 Jonsson AK, Horvath-Puho E, Hagg S. et al. Antipsychotics and risk of venous thromboembolism: A population-based case-control study. Clin Epidemiol 2009; 01: 19-26.
• 15 Zornberg GL, Jick H. Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study. Lancet 2000; 356: 1219-1223.
• 16 Wu CS, Lin CC, Chang CM. et al. Antipsychotic treatment and the occurrence of venous thromboembolism: a 10-year nationwide registry study. J Clin Psychiatry 2013; 74: 918-924.
• 17 Bucciarelli P, Mannucci PM. The hemostatic system through aging and menopause. Climacteric 2009; 12 (Suppl. 01) 47-51.
• 18 Silverstein MD, Heit JA, Mohr DN. et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158: 585-593.
• 19 Weber MT, Maki PM, McDermott MP. Cognition and mood in perimenopause: a systematic review and meta-analysis. J Steroid Biochem Mol Biol 2014; 142: 90-98.
• 20 Falkenburg J, Tracy DK. Sex and schizophrenia: a review of gender differences. Psychosis 2014; 06: 61-69.
• 21 Chen YC, Yeh HY, Wu JC. et al. Taiwan’s National Health Insurance Research Database: administrative health care database as study object in bibliometrics. Scientometrics 2011; 86: 365-380.
• 22 Laws & Regulations Database of The Republic of China. National Health Insurance Medical Expense Declaration and Reimbursement, and Review of Medical Services. Available at http://law.moj.gov.tw/LawClass/LawCon- tent.aspx?PCODE=L0060006 Accessed January 28. 2016.
• 23 Bureau of Health Promotion, Department of Health, R. O. C. (Taiwan). Available at: http://www.hpa.gov.tw/bhpnet/web/news/news.aspx?no=200712250210 Accessed on July 23, 2015.
• 24 Lee CH, Cheng CL, Chang CH. et al. Universal pharmacological thromboprophylaxis for total knee arthroplasty may not be necessary in low-risk populations: a nationwide study in Taiwan. J Thromb Haemost 2012; 10: 56-63.
• 25 Felcher AH, Mularski RA, Mosen DM. et al. Incidence and risk factors for venous thromboembolic disease in podiatric surgery. Chest 2009; 135: 917-922.
• 26 Tamariz L, Harkins T, Nair V. A systematic review of validated methods for identifying venous thromboembolism using administrative and claims data. Pharmacoepidemiol Drug Saf 2012; (21) (Suppl. 01) 154-162.
• 27 Sultan AA, West J, Tata LJ. et al. Risk of first venous thromboembolism in and around pregnancy: a population-based cohort study. Br J Haematol 2012; 156: 366-373.
• 28 Pakzad-Vaezi KL, Etminan M, Mikelberg FS. The association between cataract surgery and atypical antipsychotic use: a nested case-control study. Am J Ophthalmol 2013; 156: 1141-1146. e1.
• 29 Chang CM, Wu KY, Liang HY. et al. Adherence patterns with first-versus second-generation antipsychotics for newly diagnosed schizophrenia in Taiwan. Psychiatr Serv 2012; 63: 504-507.
• 30 Gardner DM, Murphy AL, O’Donnell H. et al. International consensus study of antipsychotic dosing. Am J Psychiatry 2010; 167: 686-693.
• 31 Orr MW, Knox JM, Allen R. et al. The effects of neuroleptic drugs on 5-hydroxytryptamine induced platelet aggregation in schizophrenic patients. Br J Clin Pharmacol 1981; 11: 255-259.
• 32 Isah AO, Rawlins MD, Bateman DN. Clinical pharmacology of prochlorperazine in healthy young males. Br J Clin Pharmacol 1991; 32: 677-684.
• 33 Kroeze WK, Hufeisen SJ, Popadak BA. et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003; 28: 519-526.
• 34 Roth BL, Lopez E, Beischel S. et al. Screening the receptorome to discover the molecular targets for plant-derived psychoactive compounds: a novel approach for CNS drug discovery. Pharmacol Ther 2004; 102: 99-110.
• 35 Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res 2011; 46: 399-424.
• 36 Tadrous M, Gagne JJ, Sturmer T. et al. Disease risk score as a confounder summary method: systematic review and recommendations. Pharmacoepidemiol Drug Saf 2013; 22: 122-129.
• 37 Bjerre LM, LeLorier J. Expressing the magnitude of adverse effects in case-control studies: “the number of patients needed to be treated for one additional patient to be harmed”. Br Med J 2000; 320: 503-506.
• 38 Masopust J, Maly R, Andrys C. et al. Markers of thrombogenesis are activated in unmedicated patients with acute psychosis: a matched case control study. BMC Psychiatry 2011; 11: 2.
• 39 Hsu WY, Lane HY, Lin CL. et al. A population-based cohort study on deep vein thrombosis and pulmonary embolism among schizophrenia patients. Schizophr Res 2015; 162: 248-252.
• 40 Spencer FA, Emery C, Lessard D. et al. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med 2006; 21: 722-727.
• 41 Lee CH, Cheng CL, Lin LJ. et al. Epidemiology and predictors of short-term mortality in symptomatic venous thromboembolism. Circ J 2011; 75: 1998-2004.
• 42 Lee CH, Lin LJ, Cheng CL. et al. Incidence and cumulative recurrence rates of venous thromboembolism in the Taiwanese population. J Thromb Haemost 2010; 08: 1515-1523.
• 43 Ishiguro C, Wang X, Li L. et al. Antipsychotic drugs and risk of idiopathic venous thromboembolism: a nested case-control study using the CPRD. Pharmacoepidemiol Drug Saf 2014; 23: 1168-1175.
• 44 Bressolle F, Bres J, Faure-Jeantis A. Absolute bioavailability, rate of absorption, and dose proportionality of sulpiride in humans. J Pharm Sci 1992; 81: 26-32.
• 45 Chang WH, Lam YW, Jann MW. et al. Pharmacokinetics of haloperidol and reduced haloperidol in Chinese schizophrenic patients after intravenous and oral administration of haloperidol. Psychopharmacology 1992; 106: 517-522.
• 46 Liperoti R, Pedone C, Lapane KL. et al. Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Arch Intern Med 2005; 165: 2677-2682.
• 47 Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d’Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost 2000; 83: 657-660.
• 48 Buesing KL, Mullapudi B, Flowers KA. Deep venous thrombosis and venous thromboembolism prophylaxis. Surg Clin North Am 2015; 95: 285-300.
• 49 Gould MK, Garcia DA, Wren SM. et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e227S-77S.
• 50 Nunez MJ, Villalba JC, Cebrian E. et al. Venous thromboembolism in immobilized patients with dementia. Findings from the RIETE registry. Thromb Res 2012; 130: 173-177.